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A B S T R A C T
Objective: New onset refractory status epilepticus (NORSE) is a recently described entity and has been
difﬁcult to treat because the etiology is often cryptogenic. Our aim in each case was to stop status
epilepticus while simultaneously searching for the etiology.
Methods: We describe three patients who presented with NORSE, who were refractory to multiple
anticonvulsants and general anesthetics for at least 5 days. All patients had an extensive evaluation
including MRI brain, CSF studies, radiologic scans for malignancy and serological autoimmune and
infectious investigations.
Results: Each patient responded dramatically to the use of plasma exchange therapy with cessation of
status epilepticus by the fourth day of treatment. Although an etiology was sought after, no appropriate
cause for NORSE could be found.
Conclusion: We propose early use of plasma exchange therapy (Class IV evidence) in hopes to prevent the
complications of status epilepticus and prolonged hospitalization.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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New onset refractory status epilepticus (NORSE) in adults can
be difﬁcult to treat especially in cases where the etiology
remains unknown, despite extensive evaluation including
autoimmune, infectious and metabolic studies.1 These patients
present a therapeutic challenge because outcome is often poor
due to prolonged hospitalization. Etiology is often presumed to
be viral encephalitis based on MR imaging abnormalities or mild
CSF pleocytosis, however, some of these changes may be due to
the seizure activity itself.2,3 We report our experience with 3
patients with NORSE who responded to plasma exchange
therapy after multiple anticonvulsants and general anesthetics
failed. While much is still unknown about this disease entity, our
experience suggests that immune therapies should be consid-
ered early on in the hospital course to prevent high morbidity
and mortality.Abbreviations: NORSE, new onset refractory status epilepticus; cEEG, continuous
EEG; PE, plasma exchange; HC, hippocampal.
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2.1. Patient 1
A 43-year-old African-American woman with no prior history of
seizures and no risk factors for epilepsy presented with her ﬁrst
generalized tonic–clonic seizure and a preceding ﬂu-like illness.
Initial EEG showed background slowing and a brain MRI was
normal. She was discharged home with phenytoin, but developed
progressive confusion over the next 3 days and was readmitted. A
stat EEG showed bitemporal independent focal seizures. She was
initiated on fosphenytoin and levetiracetam intravenously. Her
CSF analysis, MRI brain and laboratory data are shown in Table 1
and Fig. 1B. The MRI showed bilateral hippocampal hyperinten-
sities, suspicious for limbic encephalitis. Her continuous EEG
(cEEG) monitoring showed approximately 2 seizures/h originating
from bilateral temporal lobes lasting 30–90 s (Fig. 1A). Given no
improvement in seizures on EEG, she was treated with phenobar-
bital, then propofol infusion and was ﬁnally placed in a
pentobarbital coma to achieve burst suppression of EEG activity
for 48 h. Seizures returned promptly when pentobarbital was
lightened and so the barbiturate coma was repeated again for 96 h.
A trial of methylprednisolone 1 g daily for 3 days was given
simultaneously with no improvement and seizures resumed as
pentobarbital was withdrawn. On day 18 of hospitalization,
plasma exchange (PE) therapy was instituted for 5 days, as she
remained on a midazolam infusion. On the fourth day of treatment,
her EEG began to improve with resolution of seizures and thevier Ltd. All rights reserved.
Table 1
Comparison of presentation, investigations and treatment among 3 patients.
Patient 1 2 3
Initial EEG Independent bilateral
partial-onset seizures
Right temporal lobe seizures Generalized seizures
MRI brain Bilateral hippocampal
(HC) hyperintensities
Bilateral HC hyperintensities,
greater on the right
Bilateral HC hyperintensities
Maximally abnormal CSF WBC: 62 (98% L) WBC: 0 WBC: 9 (20% N, 69% L, 11% M)
Protein: 29.7 mg/dl Protein: 43.6 mg/dl Protein: 37.9 mg/dl
Glucose: 57 mg/dl Glucose: 149 mg/dla Glucose: 72 mg/dl
Infectiousb Negative Negative Serum Mycoplasma pneumoniae IgM positivec
Paraneoplastic paneld Negative including
anti-VGKC antibody (Ab),
CT chest, abdomen, pelvis
Negative including anti-VGKC
Ab, CT chest, abdomen, pelvis,
testicular US
Negative including anti-NMDAR Ab and
anti-VGKC Ab, CT chest, abdomen, MRI pelvisOther imaging for evaluation
of malignancy
Antiepileptics used in sequence Fosphenytoin, levetiracetam,
phenobarbital
Carbamazepine, fosphenytoin,
levetiracetam, lacosamide
Fosphenytoin, levetiracetam, lacosamide,
valproic acid, phenobarbital, lorazepam
Continuous IV anesthetics used Pentobarbital, midazolam None Propofol, pentobarbital, ketamine, midazolam,
lorazepam
Overall outcome Mild impaired memory,
rare seizures
Moderate impaired memory,
partial complex seizures
Death secondary to bowel necrosis and
hospice status
a Patient 2 had uncontrolled type 2 diabetes mellitus.
b Infectious studies done in all 3 patients included testing for cryptococcus, Coccidioides immitis, HSV types 1 and 2, VZV, CMV, EBV, WNV, enteroviruses, arboviruses, TB,
VDRL, bacterial and fungal cultures in CSF and serum.
c A repeat test 13 days later showed titers were negative for IgM and positive for IgG, however, Mycoplasma was never detected in the CSF by PCR or in respiratory cultures,
cold agglutinins and chest radiograph were also negative.
d Antibodies to the following: ANNA-1, -2, -3, PCA-1, -2, PCA-Tr, Amphiphysin, CRMP-5 IgG, striational muscle, P/Q type voltage gated calcium channel, N-type voltage
gated calcium channel, Ach receptor binding, Ach ganglionic neuronal, glial nucleus. The ﬁrst patient had an earlier paraneoplastic panel from 2009 which tested antibodies to
the following: ANNA-1, -2, anti-neutrophil, Purkinje screen, potassium gate MPO, serine protease. L, lymphocyte; N, neutrophil; M, macrophage; anti-VGKC Ab, anti-voltage-
gated potassium channel; anti-NMDAR, anti-NMDA receptor.
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bital and phenytoin. She did not have any further seizures and was
discharged 1 week later. She went to acute rehabilitation on 2
anticonvulsants, valproic acid and levetiracetam. At follow-up, she
has partial complex seizures characterized by staring and
confusion twice a month. Her MRI brain one year later showed
resolution of hippocampal hyperintensities.
2.2. Patient 2
A 51-year-old Hispanic male initially presented with a febrile
illness and a suspected complex partial seizure. However, he had
normal CSF ﬁndings and routine EEG. He was started on
carbamazepine, but stopped the medication 2 weeks later on his
own. Four months later, he returned with a 5-day history of
confusion and lethargy. His CSF, MRI and laboratory evaluation are
shown in Table 1 and Fig. 1C. An initial EEG showed intermittent
focal seizures emanating from the right temporal region lasting
from 20 to 120 s interspersed by a background of mild diffuse
slowing. Initial MRI of the brain showed hyperintensities in
bilateral hippocampi with subtle enhancement noted on the right.
He was placed on cEEG monitoring and treated with fosphenytoin
followed by levetiracetam and lacosamide, however, there was no
improvement in mental status. On day 5 of hospitalization, plasma
exchange was instituted for 5 days as he was maintained on the
above anticonvulsants. After completing plasma exchange, anti-
epileptic medication was gradually weaned and seizures did not
recur. Eventually, he was discharged on 2 anticonvulsants,
phenytoin and lacosamide. At 6-month follow-up, he has
recovered well, though he reports short-term memory loss and
inability to return to work.
2.3. Patient 3
A 39-year-old previously healthy Caucasian/African-American
woman presented with a ﬂu-like illness 5 days prior to her ﬁrstgeneralized tonic–clonic seizure. She was lethargic and confused at
presentation. An initial EEG showed multiple bilateral indepen-
dent seizures clinically characterized by eye blinking. She was
initially treated with lorazepam followed by fosphenytoin and
levetiracetam. A cEEG showed non-convulsive status epilepticus
with bilateral periodic discharges at 2–3 Hz interspersed by brief
electrographic seizures lasting 60–120 s. A propofol infusion
initially suppressed seizures, but they returned promptly during
weaning. Valproic acid and lacosamide were added, but did not
improve SE. She was then placed in a pentobarbital coma on day
10. CSF, serological studies and brain MRI data are shown in Table 1
and Fig. 1D. She had serial brain MRIs which showed increasingly
hyperintense hippocampal changes. Each time the pentobarbital
infusion was decreased, bilateral independent periodic discharges
along with intermittent independent bilateral focal seizures
returned. During the second week, a 5-day course of intravenous
immunoglobulin therapy followed by 5 days of high dose
methylprednisolone did not improve her status. She developed
an acute abdomen and at emergent laparotomy, was found to have
severe bowel infarction. This was presumably due to prolonged use
of vasopressors and nearly 90% of her bowels were resected. After
surgery, given no improvement on EEG, other anesthetics
including ketamine, midazolam and lorazepam infusions were
attempted, but she continued to have seizures while on maximal
doses of each of these agents. On day 29 of hospitalization, PE was
instituted for 5 days. With simultaneous weaning of anesthetic
infusions, she began opening her eyes spontaneously to voice and
follow some commands. Her EEG showed diffuse slowing with
frequent epileptiform discharges during sleep, but no further
seizures. She was weaned off of all anesthetic agents and her
seizures were controlled with oral lorazepam, phenobarbital,
levetiracetam and lacosamide. However, her bowel condition
deteriorated and she was eventually sent to hospice where she
died quickly from respiratory failure. At autopsy, she was found to
have necrotic bowel proximal to her ostomy site along with
nonspeciﬁc inﬂammation of bilateral hippocampi.
Fig. 1. Electrographic status epilepticus and MRI brain ﬁndings. (A) Bilateral temporal lobe seizures emanating from the right hemisphere and emanating from the left
hemisphere several minutes later in patient 1. Noncontrast MRI brain T2-weighted images of (B) Patient 1 on day 19, (C) Patient 2 on day 10 and (D) Patient 3 on day 21 of
hospitalization, each showing hippocampal hyperintensities. There were no associated areas of restricted diffusion in any of the patients. Patient 2 had right temporal lobe
enhancement that resolved by the last day of hospitalization (day 10).
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Our case series suggest that PE may be a beneﬁcial in cases of
NORSE even when etiology is unclear and typical paraneoplastic or
anti-neuronal antibodies are not detected. There have been
isolated case reports showing successful use of immune-modulat-
ing therapy in such cases.4,5 While the etiology was cryptogenic in
each of our patients, it is certainly possible there are other anti-
neuronal antibodies that have not yet been discovered and further
testing of these patients’ serum and CSF against animal models
would be revealing.6 We also could not test for the full range of
known antibodies for proprietary reasons. Plasma exchange is also
not selective, but removes other soluble factors including
cryoglobulins, plasma proteins, immune complexes that may have
contributed to SE. Of importance, each patient presented primarily
with seizures and not psychiatric symptoms, but we can surmise
that likely a portion of NORSE patients have some form of limbic
encephalitis. However, diagnosis conﬁrmation should not delay
treatment. Also, the duration of SE should not deter aggressive
treatment as it has not been shown to be a predictor of prognosis
beyond the ﬁrst few hours.7 The average time for our patients to
receive plasma exchange was 17 days from the time of initial
hospitalization.
The use of multiple anti-epileptic agents and general anes-
thetics in these cases can cause severe cardiac, respiratory, and
hemodynamic compromise8 and unfortunately, our third patient
suffered irreversible abdominal ischemic injury prior to cessation
of her SE. One large series reported poor outcomes in about half of
patients with RSE, with death (35%), severe neurological deﬁcit
(13%), mild neurological deﬁcit (13%), and a minority had recovery
to baseline (35%).9 We suspect neurologists are more apt to usemultiple anti-epileptic agents and general anesthetics in NORSE
patients because these are generally previously healthy, young
individuals. However, based upon our experience PE may be a
potential beneﬁcial therapy in cases of NORSE. A recent guideline
for refractory status epilepticus also suggested using non-
pharmacologic options as a part of their treatment algorithm.10
Unfortunately, the nature of the NORSE makes it difﬁcult to
perform randomized controlled studies. But until then, we propose
that plasma exchange should be considered in the treatment
repertoire in cryptogenic NORSE cases, earlier rather than later to
prevent associated morbidity and mortality.
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